ABI-03

N/A

Report date: 2024/09/27 09:46:20
NME

Base Information

Drug NameABI-03
Drug Alias NameABI-03
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvanti Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvanti Biosciences Inc
Inactive CompaniesN/A
Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A